Resistance to insulin is a feature of patients with type 2 diabetes mellitus (T2D) and the insulin resistance syndrome. PC-1, a class II plasma membrane exoprotein inhibits the IR alpha subunit in a region between residues 485-599. This IR region links the alpha subunit ligand binding domain to the beta subunit tyrosine kinase domain. In most subjects with insulin resistance, we and others have found PC-1 in muscle and other tissues is either over expressed or is in a more active form (Q allele). Transfection and overexpression of PC-1 into cultured cells selectively reduces both IR tyrosine kinase activity and IR signaling. We now find that human PC-1 overexpression in mouse muscle and liver causes in vivo insulin resistance and diabetes. We hypothesize, therefore, that PC-1 is a major cause of insulin resistance. Herein we plan to document that PC-1 is an important regulator of insulin action, define how PC-1 interacts with the IR, and employ strategies both in vitro and in vivo to antagonize PC-1. We propose the following: First, we plan to metabolically phenotypically characterize mice that are over expressing the various alleles of PC-1. We will employ mice with adenovirus-mediated PC-1 overexpression in liver, and transgenic mice with general and tissue-specific PC-1 overexpression. Second, employing our animal models of PC-1 overexpression, we will investigate whether anti PC-1 monoclonal antibodies, PC-1 RNAi, and PC-1 antisense oligomers will lower PC-1 levels and improve insulin action. To regulate PC-1 levels, we will also use the Tet off/on system. Third, because we have data both in vitro and in vivo indicating that PC-1 directly interacts with the IR alpha subunit, we will investigate the interactions of PC-1 with the IR by elucidating how and where PC-1 binds to the IR. For this purpose, we will employ direct binding studies. In addition, mutants of both the IR and PC-1 will be produced to locate discrete sites of protein-protein interaction. By defining the contact points between PC-1 and the IR, we have the potential to devise strategies to inhibit this interaction. Fourth, PC-1 content in cultured fibroblasts and muscle biopsy closely correlate. Therefore, employing fibroblasts from insulin resistant patients, the mechanisms that cause PC-1 overexpression in insulin resistant humans will be explored. We will determine therefore whether PC-1 overexpression in fibroblast is caused by transcriptional and/or post-transcriptional mechanisms.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK056933-08
Application #
7619515
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Silva, Corinne M
Project Start
2001-06-01
Project End
2011-04-30
Budget Start
2009-05-01
Budget End
2011-04-30
Support Year
8
Fiscal Year
2009
Total Cost
$314,253
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Chiefari, Eusebio; Tanyolaç, Sinan; Paonessa, Francesco et al. (2011) Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA 305:903-12
Tanyolac, Sinan; Bremer, Andrew A; Hodoglugil, Ugur et al. (2009) Genetic variants of the ENPP1/PC-1 gene are associated with hypertriglyceridemia in male subjects. Metab Syndr Relat Disord 7:543-8
Tanyolac, Sinan; Mahley, Robert W; Hodoglugil, Ugur et al. (2008) Gender differences in the relationship of ENPP1/PC-1 variants to obesity in a Turkish population. Obesity (Silver Spring) 16:2468-71
Goldfine, Ira D; Maddux, Betty A; Youngren, Jack F et al. (2008) The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev 29:62-75
Meyre, David; Bouatia-Naji, Nabila; Tounian, Agnes et al. (2005) Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nat Genet 37:863-7
Dong, Hengjiang; Maddux, Betty A; Altomonte, Jennifer et al. (2005) Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes 54:367-72